<DOC>
	<DOCNO>NCT02873195</DOCNO>
	<brief_summary>This randomized phase II trial study well atezolizumab capecitabine without bevacizumab work treat patient colorectal cancer respond treatment spread place . Monoclonal antibody , atezolizumab bevacizumab , may interfere ability tumor cell grow spread . Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving atezolizumab capecitabine bevacizumab may better way treat colorectal cancer .</brief_summary>
	<brief_title>Capecitabine Bevacizumab With Without Atezolizumab Treating Patients With Refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate efficacy capecitabine/bevacizumab + atezolizumab , compare capecitabine/bevacizumab + placebo refractory metastatic colorectal cancer ( mCRC ) measure progression-free survival ( defined time randomization first occurrence progression base Response Evaluation Criteria Solid Tumors version 1.1 , clinical progression , death cause study determine investigator ) . SECONDARY OBJECTIVES : I . To estimate efficacy capecitabine/bevacizumab + atezolizumab , compare capecitabine/bevacizumab + placebo refractory mCRC measure objective response rate ( define partial response plus complete response ) determine investigator use Response Evaluation Criteria Solid Tumors version 1.1 immune-related response criterion ( irRC ) . II . To estimate efficacy capecitabine/bevacizumab + atezolizumab compare capecitabine/bevacizumab + placebo refractory mCRC measure overall survival ( define death cause time randomization study completion ) . III . To evaluate safety tolerability atezolizumab combination bevacizumab capecitabine refractory mCRC measure serious adverse event adverse event &gt; = grade 3 accord National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 . TERTIARY OBJECTIVES : I . To explore correlation tissue blood base biomarkers clinical outcome . OUTLINE : Patients randomize 1 2 arm . ARM I ( ATEZOLIZUMAB , BEVACIZUMAB , CAPECITABINE ) : Patients receive atezolizumab intravenously ( IV ) 60 minute day 1 , bevacizumab IV 30-90 minute day 1 , capecitabine orally ( PO ) twice daily ( BID ) day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . ARM II ( PLACEBO , BEVACIZUMAB , CAPECITABINE ) : Patients receive placebo IV 60 minute day 1 , bevacizumab IV 30-90 minute day 1 , capecitabine PO BID day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 12 week thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Histologically confirm metastatic colorectal cancer progress regimen contain fluoropyrimidine ( e.g. , 5fluorouracil capecitabine ) , oxaliplatin , irinotecan , bevacizumab antiEGFR antibody ( tumor RAS wildtype ) , treatment tolerate contraindicate Measurable disease ; Note : previously irradiate site include documented disease progression site Capecitabine bevacizumab consider appropriate treatment patient Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 Absolute neutrophil count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin = &lt; 1.5 X upper limit normal ( ULN ) ; patient know Gilbert 's syndrome serum bilirubin = &lt; 3 X ULN may enroll Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 1.5 X ULN ; &lt; 3 X ULN know hepatic metastasis Hemoglobin &gt; = 9 g/dL continuation erythropoietin product permit ; hemoglobin must stable &gt; = 9 g/dL &gt; = 14 day without blood transfusion maintain hemoglobin level Calculated creatinine clearance must &gt; = 50 ml/min use CockcroftGault formula 24 hour urine The following laboratory value obtain = &lt; 14 day prior randomization Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) /international normalize ratio ( INR ) = &lt; 1.5 X ULN anticoagulated ; within local institutional guideline per local physician anticoagulated Negative pregnancy test do = &lt; 7 day prior randomization , woman childbearing potential Provide inform write consent Willingness return enrol institution followup ( active monitoring phase study ) Willingness provide tissue blood sample correlative research purpose Life expectancy &gt; = 3 month Any follow : Pregnant woman Nursing woman Women childbearing potential must agree use two form adequate contraception time initial consent , duration study participation , &gt; = 90 day last dose study drug ; medically acceptable contraceptive include : ( 1 ) surgical sterilization ( tubal ligation hysterectomy ) , ( 2 ) approve hormonal contraceptive ( birth control pill , patch , implant injection ) , ( 3 ) barrier method ( condom diaphragm ) use spermicide , ( 4 ) intrauterine device ( IUD ) ; contraceptive measure Plan B , sell emergency use unprotected sex , acceptable method routine use ; postmenopausal woman must amenorrheic least 2 year consider nonchildbearing potential ; sexually active men must use least one form adequate contraception time initial consent , duration study participation , &gt; = 90 day last dose study drug Chemotherapy , biologic anticancer therapy , central field radiation therapy = &lt; 28 day prior randomization ; Note : local stereotactic radiation = &lt; 14 day prior randomization Any investigational agent = &lt; 28 day 5 halflives prior randomization ( whichever longer ) Prior treatment atezolizumab another PDL1/PD1 therapy History allergic reaction attribute therapeutic antibody ; Note : patient reaction chimeric antibody may permit case case basis approval study chair contact data manager Known untreated central nervous system ( CNS ) metastases ; Note : patient radiate resected lesion permit , provide lesion fully treat inactive , patient asymptomatic , steroid administer purpose = &lt; 30 day prior randomization Inadequately control hypertension ( defined average systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) History hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) grade II great congestive heart failure History myocardial infarction , unstable angina , cardiac vascular stenting , angioplasty , surgery = &lt; 12 month prior randomization Active coronary heart disease evidence angina require medication prevent angina History stroke transient ischemic attack , arterial thrombosis = &lt; 12 month prior randomization Symptomatic peripheral vascular disease Any significant vascular disease ( e.g. , aortic aneurysm , aortic dissection , carotid stenosis require medical surgical intervention , include angioplasty stenting ) Any previous National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade 4 venous thromboembolism Clinicallysignificant evidence bleed diathesis coagulopathy judge treat physician History active gastrointestinal ( GI ) bleed major bleed = &lt; 12 month prior randomization ; Note : patient resolution predispose risk factor ( e.g. , resection bleed tumor , treatment endoscopic documentation resolve ulcer ) also exclude Major surgical procedure , open biopsy , significant traumatic injury = &lt; 56 day prior randomization Anticipation need major surgical procedure = &lt; 6 month randomization Minor surgical procedure = &lt; 7 day prior randomization ; exception : insertion indwell catheter percutaneous needle biopsy = &lt; 48 hour prior randomization History intraabdominal abscess = &lt; 6 month prior randomization ; Note : affected area surgically resect , risk area , patient may enroll History abdominal significant fistula , gastrointestinal organ perforation ; Note : affected area surgically resect , risk area , patient may enroll Serious , nonhealing wound , ulcer , bone fracture judge treat physician Known proteinuria define &gt; = 2+ protein urinalysis ( UA ) &gt; = 1 gram protein 24 hour urine collection Intolerance bevacizumab define NCI CTCAE grade 3 grade 4 toxicity attribute agent require discontinuation bevacizumab ( e.g. , arterial thromboembolism [ ATE ] , perforation , wound heal difficulty , proteinuria , reversible posterior leukoencephalopathy syndrome [ RPLS ] ) ; Note : patient prior grade 3 bevacizumabrelated hypertension may permit hypertension manageable standard oral antihypertensive judge treat physician Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Impairment GI function GI disease may significantly alter capecitabine drug absorption Active inflammatory bowel disease History diverticulitis , chronic ulcerative low GI disease Crohn 's disease ulcerative colitis , symptomatic low GI condition might predispose perforation History autoimmune disease include , limited , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjogren 's syndrome , Bell 's palsy , GuillainBarre syndrome , multiple sclerosis , autoimmune thyroid disease , vasculitis , glomerulonephritis ; Note : patient history autoimmunerelated hypothyroidism stable dose thyroid replacement hormone may eligible study Active current infection history recurrent bacterial , viral , fungal , mycobacterial infection , include limited tuberculosis atypical mycobacterial disease , hepatitis B C , herpes zoster , HIV , exclude fungal infection nail bed Vaccination live attenuate vaccine = &lt; 28 day prior randomization ; Note : type vaccine , include inactivated/killed , toxoid ( inactivated toxoid ) , subunit/conjugate permitted time Any reversible treatmentrelated toxicity resolve NCI CTCAE grade = &lt; 1 except neuropathy Other concurrent severe and/or uncontrolled medical disease , psychiatric illness , social situation , could compromise safety treatment judge treat physician ; Note : include limited : severely impaired lung function , uncontrolled diabetes ( history consistent blood glucose reading 300 mg/dL less 50 mg/dL ) , severe infection , severe malnutrition , ventricular arrhythmia , know active vasculitis cause , tumor invasion major blood vessel , chronic liver renal disease , active upper GI tract ulceration Unwilling unable comply protocol Current recent ( = &lt; 10 day prior randomization ) use aspirin ( &gt; 325 mg/day ) , clopidogrel ( &gt; 75 mg/day ) Current recent ( = &lt; 10 day prior randomization ) use therapeutic oral parenteral anticoagulant thrombolytic agent therapeutic purpose , unless patient stable dose anticoagulant least 2 week time randomization ; Note : use fulldose oral parenteral anticoagulant permit long INR activate partial thromboplastin time ( aPTT ) within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant &gt; = 14 day time randomization ; prophylactic use anticoagulant allow History recent diagnosis demyelinate disease History carcinoma = &lt; 3 year ; exception : risk recurrence know 5 % time randomization Current recent ( = &lt; 90 day prior randomization ) endoluminal stent stomach , bowel , colon rectum Colonoscopy , sigmoidoscopy , proctoscopy = &lt; 7 day prior randomization Current recent ( = &lt; 28 day prior randomization ) use sorivudine , brivudine , St. John 's wort Primary secondary immunodeficiency ( history currently active ) unless relate primary disease investigation Prior allogeneic bone marrow transplantation prior solid organ transplantation Treatment systemic immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) = &lt; 14 day prior randomization ; exception : patient receive acute , lowdose , systemic immunosuppressant medication ( e.g . onetime dose dexamethasone nausea ) eligible ; use inhale corticosteroid mineralcorticoids ( e.g . fludrocortisone ) patient orthostatic hypotension adrenocortical insufficiency allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>